Skip to content

CMTA Press Room

Official News From Charcot-Marie-Tooth Association

CMTA’s Press Room Is Where We Share News That Shapes Not Only the Future of CMT Research but Real Impact Today. From Funding Announcements to Trial Updates, This Is Where Progress Moves From Idea to Action.


  • CMTA Invests $141,000 to Study Hearing and Balance to Develop Better Clinical Trial Outcome Measures in Charcot-Marie-Tooth Disease

    CMTA Invests $141K in Hearing and Balance Study

    CMTA is supporting a two-year research project examining hearing and balance signaling to strengthen outcome…

  • CMTA Appoints David Stark, MD, and Catherine Illingworth to Board of Directors, Expanding Clinical and Biotech Expertise

    CMTA Appoints David Stark and Catherine Illingworth to Board of Directors

    CMTA welcomes David Stark, MD, and Catherine Illingworth to its Board of Directors, strengthening clinical…

  • CMTA Addresses the Critical Delivery Challenge Underlying CMT Treatment Development through Four Key Investments

    Solving the CMT Treatment Delivery Challenge

    CMTA announced $523,000 in funding for four research projects focused on solving one of the…

  • CMTA Appoints Wendy Arnone as Board Chair

    CMTA Appoints Wendy Arnone as Board Chair

    CMTA has appointed Wendy Arnone as board chair, succeeding Gilles Bouchard, who has led the…

  • CMTA Invests $100,000 in EverTree Bio to Support Cutting-Edge Therapeutic Research for CMT1A

    CMTA Invests $100,000 in EverTree Bio

    CMTA announces a $100,000 investment in EverTree Bio to support continued development of an early-stage…

  • Charcot-Marie-Tooth Association Appoints Catie Coman as Chief Marketing Officer

    CMTA Appoints Catie Coman Chief Marketing Officer

    Coman brings more than 15 years of experience in patient advocacy and has worked with…

  • CMTA Invests $281,339 to Advance Treatments for CMT1A

    CMTA Invests $281,339 to Advance Treatments for CMT1A

    The newly funded study will test whether molecules originally in development as cancer therapeutics can…

  • CMTA-INC Alliance Announces 2025 Inherited Neuropathies Fellowship Recipient: Orthopedic Surgeon to Focus on Improving Outcomes for People with CMT

    CMTA–INC Alliance Announces 2025 Fellowship Recipient

    The CMTA–INC Alliance announced the 2025 Inherited Neuropathies Fellowship recipient, supporting clinical research focused on…

  • CMTA Invests $210K in Long-Read Sequencing to Accelerate CMT Gene Discovery

    $210K to Unlock CMT Gene Discoveries

    CMTA is investing $210,000 in long-read sequencing to uncover hidden gene mutations in undiagnosed CMT…

  • CMTA’s $300K Investment in CRISPR for CMT2A

    CMTA’s $300K Investment in CRISPR for CMT2A

    CMTA announced a $300,000 CMTA-STAR investment supporting CRISPR-based gene editing research aimed at selectively silencing…

  • CMTA Fuels Breakthrough Imaging Research to Address CMT2A’s Cellular Weakness

    CMTA-Sponsored Research to Address CMT2A’s Cellular Weakness

    CMTA announced a $90,860 CMTA-STAR investment supporting advanced imaging research to examine how MFN2 mutations…

  • CMTA Invests $423K in Transformative Genomic Research to Advance CMT Diagnostics

    Solving CMT: CMTA Invests $423K in Gene Discovery

    CMTA is investing $423,000 in advanced genomic research to close diagnostic gaps in CMT and…

Want the latest CMT research, news, and community updates delivered to your inbox?

Sign up for CMTA’s eNews and stay connected with the latest in CMT and CMTA news and events.

Your Pathway Doesn’t End Here. Your Journey Continues.

Where to Next?